Clinical Characteristics and Outcomes of Patients Screened for but Deemed Clinically Not Suitable for Transcatheter Mitral Valve Replacement: DECLINE-TMVR Registry.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
05 2023
Historique:
received: 21 03 2022
revised: 02 12 2022
accepted: 16 01 2023
medline: 15 5 2023
pubmed: 24 1 2023
entrez: 23 1 2023
Statut: ppublish

Résumé

Transcatheter therapies are a recognized alternative intervention in patients with severe mitral regurgitation who are at high surgical risk. The purpose of this study was to characterize patients screened for transcatheter mitral valve replacement (TMVR), establish the clinical and anatomic reasons for unsuitability, and determine clinical course and early outcomes. International multicentre registry was conducted of consecutive patients screened for TMVR at 12 centres in Europe, the United States, and Canada between April 2015 and September 2018. Patient-level retrospective data were collected for all patients screened. From a total of 294 patients, 87 (30%) patients were suitable for and underwent TMVR, whereas 207 (70%) patients were unsuitable for TMVR. There was no difference in Society of Thoracic Surgeons predicted risk of mortality (6.3% ± 4.3% vs 6.7 ± 6.1%, P = 0.52) for mitral valve replacement between the groups. The most common reasons for TMVR unsuitability were mitral annular size outside therapeutic range (28%) and small predicted neo-LVOT (25%). Preprocedural multidetector computed tomographic demonstrated that patients unsuitable for TMVR had smaller predicted neo-left ventricular outflow tract (LVOT) area (318 ±192 mm Two-thirds of patients failed screening as anatomically unsuitable for TMVR. The findings of this study have important clinical implications, highlighting an unmet clinical need and provide a target for design innovation in future iterations of TMVR devices.

Sections du résumé

BACKGROUND
Transcatheter therapies are a recognized alternative intervention in patients with severe mitral regurgitation who are at high surgical risk. The purpose of this study was to characterize patients screened for transcatheter mitral valve replacement (TMVR), establish the clinical and anatomic reasons for unsuitability, and determine clinical course and early outcomes.
METHODS
International multicentre registry was conducted of consecutive patients screened for TMVR at 12 centres in Europe, the United States, and Canada between April 2015 and September 2018. Patient-level retrospective data were collected for all patients screened.
RESULTS
From a total of 294 patients, 87 (30%) patients were suitable for and underwent TMVR, whereas 207 (70%) patients were unsuitable for TMVR. There was no difference in Society of Thoracic Surgeons predicted risk of mortality (6.3% ± 4.3% vs 6.7 ± 6.1%, P = 0.52) for mitral valve replacement between the groups. The most common reasons for TMVR unsuitability were mitral annular size outside therapeutic range (28%) and small predicted neo-LVOT (25%). Preprocedural multidetector computed tomographic demonstrated that patients unsuitable for TMVR had smaller predicted neo-left ventricular outflow tract (LVOT) area (318 ±192 mm
CONCLUSIONS
Two-thirds of patients failed screening as anatomically unsuitable for TMVR. The findings of this study have important clinical implications, highlighting an unmet clinical need and provide a target for design innovation in future iterations of TMVR devices.

Identifiants

pubmed: 36690327
pii: S0828-282X(23)00054-5
doi: 10.1016/j.cjca.2023.01.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

581-589

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Ozan M Demir (OM)

Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy; Cardiology Department, St. Thomas' Hospital, London, United Kingdom. Electronic address: ozan.demir@kcl.ac.uk.

Lenard Conradi (L)

University Heart and Vascular Center Hamburg, Hamburg, Germany.

Bernard Prendergast (B)

Cardiology Department, St. Thomas' Hospital, London, United Kingdom.

Edwin Ho (E)

Department of Cardiology, Montefiore Medical Center, New York, New York, USA.

Matteo Montorfano (M)

Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy.

Alison Duncan (A)

Cardiology Department, Royal Brompton Hospital, London, United Kingdom.

Paolo Denti (P)

Cardiac Surgery Department, San Raffaele University Hospital, Milan, Italy.

Thomas Modine (T)

Centre Hospitalier Regional Universitaire de Lille, Lille, France.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Maurizio Taramasso (M)

HerzZentrum Hirslanden Zurich, Zurich, Switzerland.

Neil Fam (N)

St. Michael's Hospital, Toronto, Ontario, Canada.

Paul A Grayburn (PA)

Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, Texas, USA.

Sabine De Bruijin (S)

Cardiovascular Center, Frankfurt, Germany.

Vasileios Tzalamouras (V)

King's College Hospital, London, United Kingdom.

Ben Wilkins (B)

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Walid Ben-Ali (W)

Montreal Heart Institute, Montréal, Québec, Canada.

Annamaria Ladanyi (A)

Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy.

Sebastian Ludwig (S)

University Heart and Vascular Center Hamburg, Hamburg, Germany.

Heath Adams (H)

Cardiology Department, St. Thomas' Hospital, London, United Kingdom.

Ronak Rajani (R)

Cardiology Department, St. Thomas' Hospital, London, United Kingdom.

Alfredo N Ferreira-Neto (AN)

Quebec Heart and Lung Institute, Laval University, Québec City, Québec, Canada.

Francesco Maisano (F)

University of Zurich, Zurich, Switzerland.

Horst Sievert (H)

Cardiovascular Center, Frankfurt, Germany.

Philip MacCarthy (P)

King's College Hospital, London, United Kingdom.

Simon Redwood (S)

Cardiology Department, St. Thomas' Hospital, London, United Kingdom.

Lars Sondegaard (L)

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Antonio Colombo (A)

Invasive Cardiology Unit, Humanitas Clinical and Research Center, IRCCS, Milan, Italy.

Martin Leon (M)

Cardiology Department, New York-Presbyterian, Columbia University Medical Center, New York, New York, USA.

Azeem Latib (A)

Department of Cardiology, Montefiore Medical Center, New York, New York, USA. Electronic address: alatib@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH